Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 4/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.36 |
| ▸ | SKP1 | P63208 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.36 |
| ▸ | CETP | P11597 | 3/20 | 0.34 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.33 |
| ▸ | STK17B | O94768 | 1/20 | 0.33 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.32 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5227594 | 0.95 | CACNA1H (0.37) | CACNA1HCACNA1BCACNA1CTACR1PARP1 | |
| Hydrochloric Acid SCHEMBL5235535 | 0.79 | TACR1 (0.38) | TACR1GPBAR1 | |
| SCHEMBL19300698 | 0.78 | CETP (0.44) | CACNA1HCACNA1BCACNA1CCETP | |
| SCHEMBL6988118 | 0.78 | TACR1 (0.51) | TACR1CKS1BSKP1SKP2GPBAR1 | |
| SCHEMBL13887001 | 0.69 | CACNA1H (0.54) | CACNA1HCACNA1BCACNA1CTACR1 | |
| SCHEMBL23979680 | 0.68 | HTT (0.51) | STK17BSTK17AHTT | |
| SCHEMBL4708294 | 0.67 | MEN1 (0.38) | TACR1CKS1BSKP1SKP2CETP | |
| SCHEMBL14434370 | 0.67 | TACR1 (0.37) | TACR1GPBAR1 | |
| SCHEMBL24373446 | 0.66 | HTT (0.49) | STK17BSTK17AHTT | |
| SCHEMBL6991255 | 0.66 | CACNA1H (0.46) | CACNA1HCACNA1BCACNA1CTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1496059-B1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | KYORIN SEIYAKU KK (JP) | 2007-08-15 | — | — | EP | disclosed |
| US-7064119-B2 | Fused bicyclic pyrimidine derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-06-20 | — | — | US | disclosed |
| US-20050159409-A1 | Fused bicyclic pyrimidine derivatives | KYORIN PHARMACEUTICAL CO. LTD. (JP) | 2005-07-21 | — | — | US | disclosed |
| EP-1496059-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | Kyorin Pharmaceutical Co., Ltd. (JP) | 2005-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159409-A1 | Fused bicyclic pyrimidine derivatives | BDKRB1, BDKRB2, TACR1 | CACNA1H 544/4885CACNA1B 499/4885CACNA1C 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.